EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2024-0052 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Alejandra Castanon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Lane Clark & Peacock LLP, London, W1U 9DQ, UK. Hauptthemen laut MEDLINE: Rare Diseases, Technology Assessment, Biomedical. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The EU HTA guidance should strike a balance between evidential uncertainties and patient access, aligning with the pragmatic approaches of some member states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lane Clark & Peacock LLP, London, W1U 9DQ, UK.
- Centre for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK.
Zitieren
APA
Castanon, A., Sloan, R., Arocha, L. S., & Ramagopalan, S. V. (2024). EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0052
Vancouver
Castanon A, Sloan R, Arocha LS, Ramagopalan SV. EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0052
BibTeX
@article{Castanon2024,
author = {Castanon, Alejandra and Sloan, Rebecca and Arocha, Luisamanda Selle and Ramagopalan, Sreeram V},
title = {EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2024-0052}
}
EUVIMED